Partner
Brian Kacedon is a recognized authority in IP transactions. He has drafted and negotiated hundreds of agreements across all technologies and is designated as a Certified Licensing Professional (CLP). Brian has also successfully litigated multiple lawsuits and arbitrations based on his extensive transactional experience.
Brian focuses on patent and technology licensing and litigation. In his transactional practice, Brian assists clients in conducting market assessments for their patents, conducts licensing negotiations, drafts licensing agreements, and participates in related litigations. He routinely negotiates and drafts complex license and collaboration agreements for both small and large pharmaceutical companies, many with total payments of hundreds of millions of dollars. Brian's experience includes setting up and directing international patent licensing and enforcement programs, including one that resulted in more than 500 license agreements. One client praised Brian's ability to see both the legal and business side of transactions, saying he has an understanding of those laws in concert with what [our] business needs are in Acritas Stars.
Over the course of his career, Brian has drafted hundreds of patent, know-how, and software license agreements as well as joint development, collaboration, and settlement agreements for many industries, including pharmaceutical, medical device, software, and consumer electronics. He has assisted several leading technology companies in negotiating and drafting licenses for wireless technologies, as well as navigated related standards-setting issues.
Brian has extensive experience litigating agreement disputes. He has appeared as counsel in multiple litigations and arbitrations, including a trade secret misappropriation, for clients in industries ranging from pharmaceuticals to semiconductors. Brian has also been retained as an expert witness relating to the interpretation of license agreements.
A frequent presenter at legal and industry workshops and conferences, Brian has lectured on drafting patent and know-how licenses for the Patent Resources Group (PRG) and the Licensing Executives Society (LES), as well as other organizations. He served as an adjunct professor teaching licensing at the George Washington University Law School.
The Legal 500 U.S. has recognized Brian as one of the leading lawyers in patent licensing and transactional work and as a Next Generation Lawyer for patent licensing. He is listed in Intellectual Asset Management (IAM) magazine as one of 250 of the world's leading patent and technology licensing practitioners. IAM also named him as a leading patent litigator and for patent transactions.
Drafted and negotiated a complex license agreement for Fochon Pharmaceuticals, Ltd. relating to BCL-2 inhibitors with up to $400 million in potential development and commercial milestones.
Represented Genevant Sciences in negotiating and drafting several license and collaboration agreements for Genevant’s lipid nanoparticle technology, including agreements with Gritstone Oncology relating to COVID-19 and BioNTech relating to development of mRNA therapeutics for rare diseases.
Drafted and negotiated a complex strategic development agreement for Roivant Sciences relating to a small molecule product with potential payments of up to $600 million.
Represented a major U.S. pharmaceutical company in two arbitrations concerning a leading biologic. Finnegan’s client won both arbitrations and, in the second, was awarded its attorney fees.
Represented a U.S. pharmaceutical company in an arbitration with a former consultant and inventor. The dispute involved issues relating to inventorship and ownership, as well as the determination of royalties due under various agreements. The matter settled shortly before the hearing on favorable terms.
Represented CSRC in two arbitrations and one litigation relating to exclusive licenses and patent assignments for patents directed to treating Pompe Disease, a rare genetic disorder that is often fatal if untreated. Secured a $180 million settlement from Genzyme.
01-19-0001-6937; 01-20-0000-5081, American Arbitration Association (AAA)
Drafted and negotiated a global cross-license on behalf of a leading specialty chemicals company.
Assisted AbbVie, Inc. with multiple settlement and license agreements relating to a leading biopharmaceutical product.
Represented Dorco in patent infringement case involving cartridge shaver technology; reached a favorable settlement.
1:18-cv-01306, D. Del., Judge Stark
Represented LG Electronics in a district court litigation between the parties concerning certain standard essential patents and wireless technologies in smartphones.
2:17-cv-00458, E.D. Tex., Judge Gilstrap
Retained as expert witness on licensing matters by UTAC (Taiwan) Corp.
5:10-cv-04435, N.D. Cal., Judge Davila
Represented AbbVie in a validity and infringement dispute involving Humira® (human therapeutic antibodies), one of the best selling drugs in the world. The case settled favorably.
4:09-cv-40089, D. Mass., Judge Saylor
Represented Guidant in a patent infringement case involving coronary stents, which ended with a favorable settlement for defendant on the fourth day of jury deliberations.
1:03-cv-02604, S.D.N.Y., Judges Scheindlin, Francis
BCL-2 inhibitors licensing agreement for Fochon Pharmaceuticals, Ltd.
Lipid nanoparticle licensing and collaboration agreements for Genevant Sciences
Small molecule product development agreement for Roivant Sciences
Arbitration victory for major U.S. pharmaceutical company
Finnegan successfully represents U.S. pharmaceutical company in an arbitration
01-19-0001-6937; 01-20-0000-5081, American Arbitration Association (AAA)
Event
2024 Patent Law Institute: Critical Issues & Best Practices 2024 Patent Law Institute: Critical Issues & Best Practices
September 30 - October 1, 2024
New York
Event
U.S. Patent Litigation and Licensing Workshop: Navigating the Latest Trends and Developments in IP Licensing, PTAB Proceedings and Patent Litigation U.S. Patent Litigation and Licensing Workshop: Navigating the Latest Trends and Developments in IP Licensing, PTAB Proceedings and Patent Litigation
June 14, 2024
Taipei
IP Updates
The Federal Trade Commission’s Comprehensive Ban on Non-Competes The Federal Trade Commission’s Comprehensive Ban on Non-Competes
April 29, 2024
Event
2024 Patent Law Institute: Critical Issues & Best Practices 2024 Patent Law Institute: Critical Issues & Best Practices
September 30 - October 1, 2024
New York
Event
2024 Licensing Executives Society USA – Canada Annual Meeting 2024 Licensing Executives Society USA – Canada Annual Meeting
October 20-23, 2024
New Orleans
"Kacedon has been busy executing licensing agreements for biopharmaceutical companies and food and beverage patrons."
Intellectual Asset Management Patent 1000
"Brian Kacedon is the most experienced IP transaction attorney I have worked with over my career of over 14 years in IP licensing and portfolio growth."
The Legal 500 U.S.
"Brian Kacedon is reliable, practical and smart."
The Legal 500 U.S.
"David Mroz and Brian Kacedon are both very engaged, friendly, business-oriented and focused on enabling opportunity for clients."
The Legal 500 U.S.
“Qingyu and Brian are good listeners with an exact understanding of their clients’ needs. They resolve problems in a timely fashion and are experienced lawyers who you always learn something from.”
Intellectual Asset Management Patent 1000
"Also recommended [is] Brian Kacedon…contentious savvy gives Kacedon an edge in negotiations.”
Intellectual Asset Management Patent 1000
“Frontline dealmakers include…Brian Kacedon, a licensing maven with hardened negotiation skills born of litigation experience.”
Intellectual Asset Management Patent 1000
“Tipped for both litigation and transactions, Brian Kacedon is deemed ‘outstanding’ by economic expert witnesses.”
Intellectual Asset Management Patent 1000
“‘Smart and personable’ up-and-comer Brian Kacedon is an all-rounder who is ‘great at laying the groundwork for fruitful alliances’”.
Intellectual Asset Management Patent 1000
“Brian Kacedon is singled out by peers as a smart choice for conflict of interest referrals on licensing and related litigation.”
Intellectual Asset Management Patent 1000
“Kacedon has been cutting many deals in the biopharmaceutical sector and always has the right answer for clients who may know what they want in an agreement, but do not necessarily know what the state of the market is with respect to key deal terms.”
Intellectual Asset Management Patent 1000
“Kacedon is more than comfortable with the finer technology points in his transactions but does not hesitate to utilize the firm’s stacked roster of PhDs where it is advantageous to do so.”
Intellectual Asset Management Patent 1000
“‘An outstanding writer and tactician with excellent instincts, Brian is one of the leading experts on patent licensing in the entire life sciences industry, as well as a skilled and experienced patent litigator. He knows how his clients like to operate and tailors his work product accordingly; on a personal level, he is an incredibly friendly and reasonable individual who is a pleasure to work with.’”
Intellectual Asset Management Patent 1000
“Brian Kacedon leans into the contentious practice but is best known as one of Finnegan’s top licensing professionals.”
Intellectual Asset Management Patent 1000
“He [Brian Kacedon], John Paul and William Pratt form a strong backbone to the transactional practice.”
Intellectual Asset Management Patent 1000
“Brian Kacedon…has a wealth of expertise handling the licensing aspects of transactions, in drafting and negotiating license and collaboration agreements in addition to having litigated multiple lawsuits and arbitrations based on his extensive transactional experience.”
The Legal 500 U.S.
"Kacedon has been busy executing licensing agreements for biopharmaceutical companies and food and beverage patrons."
Intellectual Asset Management Patent 1000
"Brian Kacedon is the most experienced IP transaction attorney I have worked with over my career of over 14 years in IP licensing and portfolio growth."
The Legal 500 U.S.
"Brian Kacedon is reliable, practical and smart."
The Legal 500 U.S.
"David Mroz and Brian Kacedon are both very engaged, friendly, business-oriented and focused on enabling opportunity for clients."
The Legal 500 U.S.
“Qingyu and Brian are good listeners with an exact understanding of their clients’ needs. They resolve problems in a timely fashion and are experienced lawyers who you always learn something from.”
Intellectual Asset Management Patent 1000
"Also recommended [is] Brian Kacedon…contentious savvy gives Kacedon an edge in negotiations.”
Intellectual Asset Management Patent 1000
“Frontline dealmakers include…Brian Kacedon, a licensing maven with hardened negotiation skills born of litigation experience.”
Intellectual Asset Management Patent 1000
“Tipped for both litigation and transactions, Brian Kacedon is deemed ‘outstanding’ by economic expert witnesses.”
Intellectual Asset Management Patent 1000
“‘Smart and personable’ up-and-comer Brian Kacedon is an all-rounder who is ‘great at laying the groundwork for fruitful alliances’”.
Intellectual Asset Management Patent 1000
“Brian Kacedon is singled out by peers as a smart choice for conflict of interest referrals on licensing and related litigation.”
Intellectual Asset Management Patent 1000
“Kacedon has been cutting many deals in the biopharmaceutical sector and always has the right answer for clients who may know what they want in an agreement, but do not necessarily know what the state of the market is with respect to key deal terms.”
Intellectual Asset Management Patent 1000
“Kacedon is more than comfortable with the finer technology points in his transactions but does not hesitate to utilize the firm’s stacked roster of PhDs where it is advantageous to do so.”
Intellectual Asset Management Patent 1000
“‘An outstanding writer and tactician with excellent instincts, Brian is one of the leading experts on patent licensing in the entire life sciences industry, as well as a skilled and experienced patent litigator. He knows how his clients like to operate and tailors his work product accordingly; on a personal level, he is an incredibly friendly and reasonable individual who is a pleasure to work with.’”
Intellectual Asset Management Patent 1000
“Brian Kacedon leans into the contentious practice but is best known as one of Finnegan’s top licensing professionals.”
Intellectual Asset Management Patent 1000
“He [Brian Kacedon], John Paul and William Pratt form a strong backbone to the transactional practice.”
Intellectual Asset Management Patent 1000
“Brian Kacedon…has a wealth of expertise handling the licensing aspects of transactions, in drafting and negotiating license and collaboration agreements in addition to having litigated multiple lawsuits and arbitrations based on his extensive transactional experience.”
The Legal 500 U.S.
Award/Ranking
Finnegan Ranked Top Tier in The Legal 500 2024 Rankings Finnegan Ranked Top Tier in The Legal 500 2024 Rankings
June 13, 2024
The Legal 500Award/Ranking
46 Finnegan Attorneys Ranked in 2024 IAM Patent 1000 46 Finnegan Attorneys Ranked in 2024 IAM Patent 1000
June 6, 2024
Intellectual Asset ManagementPress Release
Former Finnegan Attorneys Return to Expand IP Transactions Practice with In-House Experience Former Finnegan Attorneys Return to Expand IP Transactions Practice with In-House Experience
October 2, 2023
Press Release
Finnegan Receives Top Rankings from Intellectual Asset Management; 46 Attorneys Ranked Finnegan Receives Top Rankings from Intellectual Asset Management; 46 Attorneys Ranked
June 30, 2023
Intellectual Asset ManagementPress Release
The Legal 500 Ranks Finnegan a Top Tier Firm for 2023 The Legal 500 Ranks Finnegan a Top Tier Firm for 2023
June 12, 2023
The Legal 500Press Release
45 Finnegan Attorneys Recommended by Intellectual Asset Management; Firm Continues to Be Top Ranked 45 Finnegan Attorneys Recommended by Intellectual Asset Management; Firm Continues to Be Top Ranked
July 8, 2022
Intellectual Asset ManagementDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.